[Ad hoc announcement pursuant to Art. 53 LR] Roche: Change in the Corporate Executive Committee in January 2023

Basel, 3 October 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Matt Sause (45), currently Head of Roche Diagnostics’ North America Region, will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.

Thomas Schinecker, the incumbent CEO of the Diagnostics Division and new Roche CEO as of 15 March 2023: “Matt Sause’s career at Roche has spanned twenty years in multiple countries across Asia, Latin America, Europe and North America in both the Diagnostics and Pharma divisions. His combination of scientific knowledge with commercial experience makes him an excellent leader for the Diagnostics division.”

Severin Schwan, currently Roche CEO, who has been proposed by the Roche Board of Directors as the new Chairman of Roche at the Annual General Meeting on 14 March 2023: “Matt Sause has had an exceptional career with Roche and I am very pleased that we can once again internally appoint a leader of his caliber to become the next CEO Roche Diagnostics”.

Matt began his career with Roche in the United States in 2002 as a Senior Molecular Account Manager and progressed in various commercial general management and global product leadership roles spanning both the Diagnostics and Pharma divisions in multiple countries such as Japan, Ireland, Peru, and South Korea. In 2018, he moved to Genentech in the United States to become Lifecycle Leader for Tecentriq Lung and Head and Neck Cancers before eventually taking over his current role as President and CEO for Roche Diagnostics North America. Matt holds a Bachelor’s degree in Microbiology from Miami University and an MBA from University of California, San Diego.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Hans Trees, PhD
Phone: +41 61 687 41 47
Nathalie Altermatt
Phone: +41 61 687 43 05
Karsten Kleine
Phone: +41 61 682 28 31
Nina Mählitz
Phone: +41 79 327 54 74


Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Sileia Urech
Phone: +41 79 935 81 48


error: Content is protected !!